|
gptkbp:instance_of
|
gptkb:healthcare_organization
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:healthcare_organization
|
|
gptkbp:associated_with
|
gptkb:neurofibromatosis_type_1
gptkb:Li-Fraumeni_syndrome
gptkb:tuberous_sclerosis
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:genetic_diversity
|
gptkb:EGFR
gptkb:PTEN
T P53
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
primary glioblastoma
|
|
gptkbp:is_characterized_by
|
rapid growth
|
|
gptkbp:is_often_used_in
|
adults
|
|
gptkbp:lifespan
|
15 months
|
|
gptkbp:location
|
frontal lobe
temporal lobe
cerebral hemispheres
|
|
gptkbp:occurs_in
|
3.19 per 100,000 people
|
|
gptkbp:research_focus
|
gptkb:vaccine
targeted therapy
tumor microenvironment
|
|
gptkbp:risk_factor
|
age
gender
exposure to radiation
|
|
gptkbp:side_effect
|
gptkb:healthcare_organization
fatigue
nausea
pain
seizures
hair loss
cognitive changes
|
|
gptkbp:social_responsibility
|
gptkb:MRI
CT scan
biopsy
poor
|
|
gptkbp:successor
|
IV
|
|
gptkbp:symptoms
|
cognitive decline
dizziness
fatigue
nausea
vomiting
confusion
seizures
vision problems
weakness
headaches
balance issues
personality changes
speech difficulties
|
|
gptkbp:treatment
|
gptkb:hospital
radiation therapy
chemotherapy
recurrence
overall survival
progression-free survival
|
|
gptkbp:type
|
gptkb:healthcare_organization
|